Alisertib (MLN8237)

Catalog No.S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 48 Publications

12 Customer Reviews

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017.. Alisertib (MLN8237) purchased from Selleck.

    Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

  • Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

    Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.
Features First orally available inhibitor of Aurora A.
Targets
Aurora A [1]
(Cell-free assay)
Aurora B [1]
(Cell-free assay)
1.2 nM 396.5 nM
In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. [2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 M4P5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXsZ4YxNjVizszN NGD2S2w4OiCq MlXZSG1UVw>? NXfPfJRvUUN3ME2wMlA1KM7:TR?= MX6yOlE{PjZ6NB?=
LS174T M1e0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX2wMlUh|ryP NHfqV3o4OiCq NIjpOVdFVVOR M4fHO2lEPTB;MD6wOUDPxE1? M{i0dFI3OTN4Nki0
T84 MoLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrQbpIxNjVizszN MWC3NkBp M4fIcWROW09? NWP3[3N5UUN3ME2wMlA6KM7:TR?= M37UflI3OTN4Nki0
LS180 NXX2NWo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TyN|AvPSEQvF2= Mn3WO|IhcA>? Ml;USG1UVw>? MkXlTWM2OD1zIN88US=> NG\i[mgzPjF|Nk[4OC=>
SW948 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU[wMlUh|ryP NETQclg4OiCq MorxSG1UVw>? MmLCTWM2OD1zIN88US=> NHnDeXgzPjF|Nk[4OC=>
HCT15 NEmyVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LRdFAvPSEQvF2= NGjGOnI4OiCq NGnIcJpFVVOR NHXWVXNKSzVyPECuOEDPxE1? MX:yOlE{PjZ6NB?=
DLD-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXuwMlUh|ryP MofoO|IhcA>? NGrCd5lFVVOR MY\JR|UxRDBwODFOwG0> NGT4TY0zPjF|Nk[4OC=>
MIP-101 M3LMfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[0NE42KM7:TR?= M37W[|czKGh? NHjlXJdFVVOR MUnJR|UxRTFizszN M4fQWlI3OTN4Nki0
SNU1544 M3[1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkOyNE42KM7:TR?= NIXWflI4OiCq NX\mTG1DTE2VTx?= NFrWWoxKSzVyPUGg{txO NHjHU5gzPjF|Nk[4OC=>
OCI-Ly10 NGf5bYREgXSxdH;4bYMhSXO|YYm= NFHFSWI4OiCq MXzEUXNQ M1SwTmlEPTB;MD6wOVgh|ryP NWDsXWIxOjV6N{izN|E>
SU-DHL2 MWHDfZRwfG:6aXOgRZN{[Xl? MXG3NkBp NX7Nc2xRTE2VTx?= MoHDTWM2OD1yLkCxJO69VQ>? NVnNbXN6OjV6N{izN|E>
OCI-LY7 NUf3W2ZLS3m2b4TvfIlkKEG|c3H5 NV7oR5RiPzJiaB?= NUT0SHFXTE2VTx?= NYHESVNKUUN3ME2wMlA5OSEQvF2= MnzoNlU5Pzh|M{G=
SU-DHL6 M3PLSmN6fG:2b4jpZ{BCe3OjeR?= MnW5O|IhcA>? MljLSG1UVw>? NEDscJlKSzVyPUCuOFgzKM7:TR?= M17ONVI2QDd6M{Ox
Jeko-1 M4rQbmN6fG:2b4jpZ{BCe3OjeR?= Mk\jO|IhcA>? M2XFVmROW09? NVO3O2p{UUN3ME2wMlAzQSEQvF2= M4XLclI2QDd6M{Ox
JVM-2 MWDDfZRwfG:6aXOgRZN{[Xl? MYW3NkBp NX7IeHBqTE2VTx?= NXnVZol6UUN3ME2wMlAyKM7:TR?= M1rSfVI2QDd6M{Ox
Rec-1 NW\KZ5R2S3m2b4TvfIlkKEG|c3H5 M3j0UlczKGh? M1H2UGROW09? M2r2TmlEPTB;MD6wPFch|ryP M4fDcFI2QDd6M{Ox
Z-138 NXvl[Y1[S3m2b4TvfIlkKEG|c3H5 MmfyO|IhcA>? M1nDb2ROW09? NVPIepFZUUN3ME2wMlAyOyEQvF2= MW[yOVg4QDN|MR?=
H9 NVP5fWJFS3m2b4TvfIlkKEG|c3H5 M4rMblczKGh? M3\hT2ROW09? NHPadlBKSzVyPUCuOkDPxE1? NG\Vc|YzPTh5OEOzNS=>
HH M{PSN2N6fG:2b4jpZ{BCe3OjeR?= M4\jfVczKGh? M3:3SGROW09? M3W3W2lEPTB;MD63JO69VQ>? NIDC[GEzPTh5OEOzNS=>
DND41 Ml7KR5l1d3SxeHnjJGF{e2G7 NX7TVIRRPzJiaB?= MUfEUXNQ MXrJR|UxRTBwMTFOwG0> NELMfHYzPTh5OEOzNS=>
CCL119 MYnDfZRwfG:6aXOgRZN{[Xl? M37ES|czKGh? MXnEUXNQ NIPWRoNKSzVyPUCuNFYzKM7:TR?= NGfxepIzPTh5OEOzNS=>
J.Cam 1.6 NGXCZpVEgXSxdH;4bYMhSXO|YYm= MkPOO|IhcA>? NGD5Wm9FVVOR NUTmcIlNUUN3ME2wMlExPSEQvF2= M3X1WlI2QDd6M{Ox
Sup-T1 MVPDfZRwfG:6aXOgRZN{[Xl? M2fOVFczKGh? NU\Ge3R5TE2VTx?= M1\JVWlEPTB;Mj6xOFIh|ryP NXn2RoZHOjV6N{izN|E>
Tib 152 MkCxR5l1d3SxeHnjJGF{e2G7 MYW3NkBp Mom4SG1UVw>? M{C0PWlEPTB;MD64JO69VQ>? NHuxe|kzPTh5OEOzNS=>
MCF7 NUXT[ppjTnWwY4Tpc44hSXO|YYm= NUnBcIppPSEQvF2= NWfsUpRZOjRiaB?= MVrEUXNQ MYXJcoR2[2W|IFeyM20h[XK{ZYP0 MkHnNlU5OzR2MEG=
MDA-MB-231 M3z6SmZ2dmO2aX;uJGF{e2G7 MlLsOUDPxE1? MWGyOEBp NVLSNldtTE2VTx?= NXqzNndXUW6mdXPld{BIOy:PIHHydoV{fA>? MUWyOVg{PDRyMR?=
MCF7 M4W3NGZ2dmO2aX;uJGF{e2G7 MX61JO69VQ>? Ml;KNlQhcA>? NFu5U2tFVVOR NGn2cGVF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOS:FRFOy M{LQclI2QDN2NECx
MCF7 MWPGeY5kfGmxbjDBd5NigQ>? MXq1JO69VQ>? NG\xVGUzPCCq MkS1SG1UVw>? MoL2SIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIFPET|I> MmDvNlU5OzR2MEG=
MCF7 Mn7ZSpVv[3Srb36gRZN{[Xl? MX[1JO69VQ>? M{nKXFI1KGh? NH\NOnRFVVOR MXjE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiY4njcIlvKEJz MlK2NlU5OzR2MEG=
MCF7 MmDTSpVv[3Srb36gRZN{[Xl? MoPUOUDPxE1? M3\ETVI1KGh? NIHlcWpFVVOR MUDJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEKxJHdi\jFxQ3nwNS=> MoCyNlU5OzR2MEG=
MCF7 NVKzNlFDTnWwY4Tpc44hSXO|YYm= MlTGOUDPxE1? MlviNlQhcA>? MXTEUXNQ NVHGOVA6UW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJAzPyCNaYCx MoDKNlU5OzR2MEG=
MDA-MB-231 MXTGeY5kfGmxbjDBd5NigQ>? M4PPdFUh|ryP MXWyOEBp NXXCeHZsTE2VTx?= M3zwW2Rm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsyN0OGQ{K= NW\Q[oc3OjV6M{S0NFE>
MDA-MB-231 M4HKc2Z2dmO2aX;uJGF{e2G7 M2HPN|Eh|ryP MVuyOEBp M{jmUGROW09? M2TpT2lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsz NGTLfJUzPTh|NESwNS=>
MDA-MB-231 Mki4SpVv[3Srb36gRZN{[Xl? NGHSPGo2KM7:TR?= M4PKb|I1KGh? M3\oTmROW09? MXPE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiY4njcIlvKEJz NIrCeIkzPTh|NESwNS=>
MDA-MB-231 NXKwcWxnTnWwY4Tpc44hSXO|YYm= NEDjbHI2KM7:TR?= NF\6bJgzPCCq NUDKZlhETE2VTx?= Mo\iTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyNUBY[WZzL1PpdFE> Mo\oNlU5OzR2MEG=
MDA-MB-231 NWrj[GR7TnWwY4Tpc44hSXO|YYm= MoDCOUDPxE1? NGq0[mYzPCCq NHPlR|lFVVOR MU\JcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEK3JGtqeDF? NX;SNlV[OjV6M{S0NFE>
MDA-MB-231 M1TNeGZ2dmO2aX;uJGF{e2G7 M{fQU|Uh|ryP NF;wOmIzPCCq MmPhSG1UVw>? MlHtTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIIC1Ny=> NHrPflEzPTh|NESwNS=>
MCF7 NXzaTotRSXCxcITvd4l{KEG|c3H5 NXToZ4R3PSEQvF2= MVSyOEBp M2PpOWROW09? NWPZO2hoUW6mdXPld{BieG:ydH;0bYMh\GWjdHi= NUTj[INqOjV6M{S0NFE>
MDA-MB-231 NVO5cZlHSXCxcITvd4l{KEG|c3H5 MmPnOUDPxE1? NH\QPHkzPCCq M{G1c2ROW09? MULJcoR2[2W|IHHwc5B1d3SrYzDk[YF1cA>? Mnq3NlU5OzR2MEG=
MCF7 MoHmSpVv[3Srb36gRZN{[Xl? NWPEb3pxOSEQvF2= M3nnUFczKGh? MkHGSG1UVw>? NFrnUGdKdmS3Y3XzJIF2fG:yaHHnbYMh\GWjdHi= NEfIc48zPTh|NESwNS=>
MDA-MB-231 NV;tPZRQTnWwY4Tpc44hSXO|YYm= M3r3OVEh|ryP MYO3NkBp NF;UdmNFVVOR MmPvTY5lfWOnczDheZRweGijZ3njJIRm[XSq NG\4UWEzPTh|NESwNS=>
U-2 OS NGXNc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7mPWk2OCEQvF2= MWCyOEBp NG[3SFVFVVOR MXvJR|UxRTF4Lk[g{txO MlK4NlU4QTJ6MUG=
MG-63 M2Xjd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\tTHR4PTBizszN NHzSSYwzPCCq MWfEUXNQ MmPpTWM2OD17LkWg{txO NVfCTYVPOjV5OUK4NVE>
U-2 OS MVLBdI9xfG:|aYOgRZN{[Xl? MXi1JO69VQ>? M3zjNVI1KGh? M3PkT2ROW09? M3X3O2lv\HWlZYOgZZBweHSxdHnjJINmdGxiZHXheIg> NHLZToEzPTd7MkixNS=>
MG-63 NEOyc4FCeG:ydH;zbZMhSXO|YYm= MmC5OUDPxE1? MXiyOEBp M1[5N2ROW09? MX3JcoR2[2W|IHHwc5B1d3SrYzDj[YxtKGSnYYTo MVGyOVc6OjhzMR?=
U-2 OS NY\ROWF6TnWwY4Tpc44hSXO|YYm= NIDOVog2KM7:TR?= MWGyOEBp M3TDTmROW09? NUTrd|VrWHKxbX;0[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq NV3idVlbOjV5OUK4NVE>
MG-63 NVPYPIVHTnWwY4Tpc44hSXO|YYm= M{nINFUh|ryP MUmyOEBp NIfVWYZFVVOR MWDQdo9ud3SnczDheZRweGijZ3njJINmdGxiZHXheIg> MUiyOVc6OjhzMR?=
PANC-1 NF33UI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV61NEDPxE1? Mm\5NlQhcA>? MnvBSG1UVw>? MV3JR|UxRTdwMTFOwG0> M{TIPFI2PjN{MkK1
BxPC-3 MlTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnL1OVAh|ryP MYKyOEBp MoHLSG1UVw>? MW\JR|UxRTZwODFOwG0> MYCyOVY{OjJ{NR?=
PANC-1 M3LhXGZ2dmO2aX;uJGF{e2G7 NVHKclZCPSEQvF2= M2frN|I1KGh? Mn:wSG1UVw>? NGrNWnJKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKEd{L12gdIhie2V? M3P2NlI2PjN{MkK1
BxPC-3 NGDP[ZVHfW6ldHnvckBCe3OjeR?= MmXrOUDPxE1? NV3hVmxKOjRiaB?= Ml;ySG1UVw>? MmO5TY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDpckBIOi:PIIDoZZNm M1K2dlI2PjN{MkK1
PANC-1 NIiwb5FHfW6ldHnvckBCe3OjeR?= MUC1JO69VQ>? M13ZdVI1KGh? NWLSdVJRTE2VTx?= NGm4dm5KdmS3Y3XzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>? MWmyOVY{OjJ{NR?=
BxPC-3 MmDZSpVv[3Srb36gRZN{[Xl? NVrwdoZuPSEQvF2= MlX1NlQhcA>? MlHGSG1UVw>? MmK5TY5lfWOnczDheZRweGijZ3njJINmdGxiZHXheIg> M17yS|I2PjN{MkK1
SKOV3 NFv2T2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfv[pN3OTByIN88US=> MoHPNlQhcA>? MW\EUXNQ MofmTWM2OD1{MD60PEDPxE1? MVOyOVYzPDd3MB?=
OVCAR4 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33KOFExOCEQvF2= NVfXNZJHOjRiaB?= NX3sTZd6TE2VTx?= NWTCS4dkUUN3ME2yNk4yOyEQvF2= MV6yOVYzPDd3MB?=
SKOV3 MUPGeY5kfGmxbjDBd5NigQ>? MWS1JO69VQ>? Ml3TO|IhcA>? NEfXbphFVVOR MojaTY5lfWOnczDHNk9OKGG{cnXzeC=> M{PDdFI2PjJ2N{Ww
OVCAR4 M2m2N2Z2dmO2aX;uJGF{e2G7 MVi1JO69VQ>? Mn33O|IhcA>? MWfEUXNQ NIDFfpVKdmS3Y3XzJGczN01iYYLy[ZN1 MViyOVYzPDd3MB?=
SKOV3 NYX5UXpnSXCxcITvd4l{KEG|c3H5 NE\UToE2KM7:TR?= M1WyfFI1KGh? M4X3fGROW09? MlHKTY5lfWOnczDhdI9xfG:|aYO= NVzQU4NYOjV4MkS3OVA>
OVCAR4 Mn\uRZBweHSxc3nzJGF{e2G7 NWH4T3VRPSEQvF2= MknBNlQhcA>? NWP3dpVmTE2VTx?= NUTm[5RMUW6mdXPld{BieG:ydH;zbZM> M3ztPFI2PjJ2N{Ww
AGS M4LFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKyOUDPxE1? MYGyOEBp NHLOc4lFVVOR NXWzV3hkUUN3ME2xPU4xQSEQvF2= MWeyOVYxQTl{Mx?=
NCI-N78 MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TWNFI2KM7:TR?= NXvS[2E2OjRiaB?= MnO4SG1UVw>? MUjJR|UxRTJ4LkOzJO69VQ>? M3voPFI2PjB7OUKz
AGS NInGdpdCeG:ydH;zbZMhSXO|YYm= MUG1JO69VQ>? NHO4[5czPCCq NVWzTJM2TE2VTx?= MkTuTY5lfWOnczDhdI9xfG:|aYO= M{XCNVI2PjB7OUKz
NCI-N78 NFnBSpNCeG:ydH;zbZMhSXO|YYm= MkO2OUDPxE1? NWjCTVhLOjRiaB?= M17E[GROW09? NHu4XJlKdmS3Y3XzJIFxd3C2b4Ppdy=> NH;4eWYzPTZyOUmyNy=>
AGS M2jpU2Z2dmO2aX;uJGF{e2G7 MkfROUDPxE1? NV25e4ZKOjRiaB?= NH\QZmhFVVOR NVzXcYhKUW6mdXPld{B1cGViYYX0c5Bp[We7 NIDJOo4zPTZyOUmyNy=>
NCI-N78 Moq2SpVv[3Srb36gRZN{[Xl? NHT5Zng2KM7:TR?= M3iwNVI1KGh? M{DIWmROW09? NHfVR5lKdmS3Y3XzJJRp\SCjdYTvdIhi\3l? M{XPVVI2PjB7OUKz
HSC-3 MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1WwelEh|ryP NGOzUow1QCCq MWXJR|UxRTBwNUSg{txO M4i1b|I2OzZ4MUSz
GB30 MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWSxJO69VQ>? M1q5W|ch\A>? Ml\6SG1UVw>? MX7JR|UxRTBwMEGxJO69VQ>? M{izVlI2OTB4NEK4
GB9 M2\nbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TDO|Eh|ryP NFPNcnQ4KGR? NETVTHZFVVOR M3Xld2lEPTB;MD6wNlQh|ryP M4\QPVI2OTB4NEK4
GB169 NHLTfm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL3NUDPxE1? NInBdW84KGR? MWrEUXNQ MWPJR|UxRTBwMEOyJO69VQ>? NGTDWFgzPTFyNkSyPC=>
T24 NULXTZQ6TnWwY4Tpc44hSXO|YYm= NEjicnIyKM7:TR?= MUi0PEBp Mn3rSG1UVw>? NI\sb2tKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 MnfkNlM1ODN4M{O=
RT4 NVS1UJNCTnWwY4Tpc44hSXO|YYm= MXGxJO69VQ>? NHG3fVc1QCCq NUC0N4NPTE2VTx?= NVrUclBkUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> MVOyN|QxOzZ|Mx?=
UM-UC-3 NFq5[G1HfW6ldHnvckBCe3OjeR?= MXyxJO69VQ>? MX[0PEBp MVzEUXNQ MWTJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 MoezNlM1ODN4M{O=
T24 NF;xcVJCeG:ydH;zbZMhSXO|YYm= NELiV|U{NjF4IN88US=> Ml6wPVYhcA>? NGPYPFVFVVOR MYHJR|UxRTBwMEOwOkDPxE1? MV[yN|QxOzZ|Mx?=
RT4 NH7GbFhCeG:ydH;zbZMhSXO|YYm= M4XscFMvOTZizszN M2nMclk3KGh? NHqyWYdFVVOR NIO5S4RKSzVyPUCuNVE6QCEQvF2= NHXNTGEzOzRyM{[zNy=>
UM-UC-3 NEO3emdCeG:ydH;zbZMhSXO|YYm= MnLRN{4yPiEQvF2= NUP5SppLQTZiaB?= NXHPXFZITE2VTx?= MkewTWM2OD1yLkC0OFkh|ryP NI\PdmMzOzRyM{[zNy=>
OVCAR-5 MXrGeY5kfGmxbjDBd5NigQ>? MX21NEBvVQ>? NYjicIl1UW6qaXLpeJMh[2WubDDtbYdz[XSrb36= MonGNlM{OzR|Mke=
SKOV3ip2 MUXGeY5kfGmxbjDBd5NigQ>? NWm5bJF4PTBibl2= NELMRYpKdmirYnn0d{Bk\WyuIH3p[5JifGmxbh?= M4CwUVI{OzN2M{K3
S462 MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrqbY0yODBizszN NWHPeIE6PzJiaB?= M{DXVmROW09? NHrMS5FCfHSnboXheIV{KGOnbHyg[5Jwf3Sq NHfhOnAzOzN{OEGxOC=>
2884 MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7ibllyOTByIN88US=> NHXDW3U4OiCq NGHrNo1FVVOR NUTxcoNQSXS2ZX71ZZRmeyClZXzsJIdzd3e2aB?= M13a[FI{OzJ6MUG0
2885 M2Gwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDjcnBtOTByIN88US=> NUL1TGJGPzJiaB?= Ml7ESG1UVw>? NGXW[pRCfHSnboXheIV{KGOnbHyg[5Jwf3Sq NGHQR2gzOzN{OEGxOC=>
CRL-2396 NGK0WnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPENWoyODBizszN NVPDbYV{f2G2ZYK= M4fROmlEPTB;MD6wPVIh|ryP NUTsZodvOjNzNUO1NlQ>
TIB-48 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWexNFAh|ryP M{m0TZdifGW{ NXrwUXNOUUN3ME2wMlA5QCEQvF2= MXSyN|E2OzV{NB?=
CRL-2396 NHPyWmhEgXSxdH;4bYMhSXO|YYm= NHjVe4MyKM7:TR?= NF7WSnc1QCCq NWW2SJFIf2G2ZYK= MUHJcoR2[2W|IHHwc5B1d3Orcx?= MWmyN|E2OzV{NB?=
TIB-48 M{mxcWN6fG:2b4jpZ{BCe3OjeR?= MoHvNUDPxE1? M174XVQ5KGh? MVj3ZZRmeg>? NX7PcVUxUW6mdXPld{BieG:ydH;zbZM> MliyNlMyPTN3MkS=
AGS NIHJXWNEgXSxdH;4bYMhSXO|YYm= NV7v[JJEOC53IN88US=> MY[yOEBp MkLZSG1UVw>? MmXoSIVkemWjc3XzJINmdGxic4Xyeol3[Wx? NEflUYczOjl5Mk[xNS=>
FLO-1 M1\aPWN6fG:2b4jpZ{BCe3OjeR?= M1PBe|AvPSEQvF2= MnLmNlQhcA>? MYDEUXNQ NUPNb3hRTGWlcnXhd4V{KGOnbHygd5Vzfmm4YXy= MUGyNlk4OjZzMR?=
OE33 M{fhdmN6fG:2b4jpZ{BCe3OjeR?= Mn3kNE42KM7:TR?= NHjmT4UzPCCq MX3EUXNQ MYHE[YNz\WG|ZYOgZ4VtdCC|dYL2bZZidA>? M3znR|IzQTd{NkGx
SKLMS NYni[FFxS3m2b4TvfIlkKEG|c3H5 MWi3OUBvVQ>? M{TvUVk3KGh? NXrsVYlGUW6mdXPld{BieG:ydH;zbZM> M1vCelIzQDJzOUm3
Leio285 NYS5XIZkS3m2b4TvfIlkKEG|c3H5 M1rVZ|c2KG6P M1jzS|k3KGh? NFfYSHZKdmS3Y3XzJIFxd3C2b4Ppdy=> Mnr1NlI5OjF7OUe=
Mes-Sa M{G4N2N6fG:2b4jpZ{BCe3OjeR?= MWi3OUBvVQ>? Mn;EPVYhcA>? NEjnWpJKdmS3Y3XzJIFxd3C2b4Ppdy=> MYeyNlgzOTl7Nx?=
DAOY M4fSfWN6fG:2b4jpZ{BCe3OjeR?= NVu2d4h{OTBizszN MWC3NkBp NITiUHZFVVOR NI\URWxKSzVyPUCuNFQh|ryP M{SyNlIzPjZ7M{O1
IMR32 M37JUWN6fG:2b4jpZ{BCe3OjeR?= M{\1W|ExKM7:TR?= Mn76O|IhcA>? MYPEUXNQ MXTJR|UxRTBwMEOg{txO Mlf2NlI3Pjl|M{W=
Molt-4 NWr1N2FZS3m2b4TvfIlkKEG|c3H5 MmX4NVAh|ryP NH7LRpI4OiCq M3XQSmROW09? MnHyTWM2OD1yLkCyJO69VQ>? NWLXdW1TOjJ4NkmzN|U>
MOLM-13 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGC1cYU{KM7:TR?= MlvyO|IhcA>? NVXBSJlRTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> MUWyNlQ5QDJ2OR?=
HL-60 M{HT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHFN{DPxE1? MnjCO|IhcA>? MXnEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NXfx[YpHOjJ2OEiyOFk>
MV4-11 Moj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC5N{DPxE1? NFHZUI84OiCq MortSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= MWOyNlQ5QDJ2OR?=
SKM-1 NF\Ub3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXqzJO69VQ>? MVi3NkBp M1rqNWRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= NXXwR3ZVOjJ2OEiyOFk>
SH2 NYm2[5pQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHBNXVzOyEQvF2= Moj2O|IhcA>? MUfEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 M4HrVVIzPDh6MkS5
NOMO-1 NFrCSmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PiS|Mh|ryP MXK3NkBp Mlf0SIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= NUnwXGtDOjJ2OEiyOFk>
OCL-AML2 NXfn[ZVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:zJO69VQ>? MWq3NkBp M1LyUWRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= NXmx[WI3OjJ2OEiyOFk>
PL-21 M{fCT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPOenI{KM7:TR?= NGr2Vok4OiCq MY\EbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 MkLyNlI1QDh{NEm=
KG-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUizJO69VQ>? MVS3NkBp MXvEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 MnO3NlI1QDh{NEm=
A172 NXTqeZNVS3m2b4TvfIlkKEG|c3H5 M1f1c|ExOCEQvF2= MXOyOEBp NECy[WRFVVOR NXvrd3BHUUN3ME2wMlEzOCEQvF2= M3jkZ|IzOjd2M{m5
U87 MlzQR5l1d3SxeHnjJGF{e2G7 M4f1c|ExOCEQvF2= MX6yOEBp MYHEUXNQ MoPCTWM2OD1yLkGwOUDPxE1? M{D0OlIzOjd2M{m5
U251 NIfTdHREgXSxdH;4bYMhSXO|YYm= NGXFfnQyODBizszN MViyOEBp MnzKSG1UVw>? NEXNU2RKSzVyPUCuNVAxKM7:TR?= MojZNlIzPzR|OUm=
T98 NFHWeJBEgXSxdH;4bYMhSXO|YYm= M4HmS|ExOCEQvF2= NIXqRpgzPCCq M3\vVWROW09? MW\JR|UxRTBwMUK1JO69VQ>? M4LFWVIzOjd2M{m5
LN18 MX7DfZRwfG:6aXOgRZN{[Xl? M1\3U|ExOCEQvF2= MkDuNlQhcA>? M2foRWROW09? NWfiV2ZLUUN3ME2wMlIyOCEQvF2= NUntepNjOjJ{N{SzPVk>
LN443 M{XTRmN6fG:2b4jpZ{BCe3OjeR?= NEP4dI0yODBizszN MUOyOEBp MWrEUXNQ M3L5TGlEPTB;MD6yNlAh|ryP MXKyNlI4PDN7OR?=
HF66 M3X6TmN6fG:2b4jpZ{BCe3OjeR?= MoS0NVAxKM7:TR?= NGjmVJYzPCCq MY\EUXNQ NWnuUm95UUN3ME2wMlIzPSEQvF2= NU\KXnI2OjJ{N{SzPVk>
HF2303 M4n2PWN6fG:2b4jpZ{BCe3OjeR?= M3jlclExOCEQvF2= NF\SdmIzPCCq MV7EUXNQ NFvUOm9KSzVyPUCuNFYxKM7:TR?= NHLtfWMzOjJ5NEO5PS=>
HF2359 NYjTd2ZxS3m2b4TvfIlkKEG|c3H5 NITZ[osyODBizszN NVvxTVBIOjRiaB?= NY[zZXhpTE2VTx?= NVj5VHJ{UUN3ME2wMlA3OCEQvF2= NVWwSItiOjJ{N{SzPVk>
HF2414 MlXKR5l1d3SxeHnjJGF{e2G7 MkTMNVAxKM7:TR?= MUmyOEBp NFnKeWRFVVOR NEfzdpdKSzVyPUCuNFgxKM7:TR?= NHTmNGgzOjJ5NEO5PS=>
A-673 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4S2WVExKM7:TR?= NVy0OHBIQTZiaB?= M2raPGROW09? NX;tVIg1UUN3ME2wMlA{OiEQvF2= M3:4WlIyPDR6NUmx
TC-32 MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2iyO|ExKM7:TR?= MkLEPVYhcA>? NVTHe3ljTE2VTx?= NHT3V2tKSzVyPUCuNFM6KM7:TR?= M2TUUlIyPDR6NUmx
TC-71 M{XOVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKxNEDPxE1? NHnkcJE6PiCq NWfx[lJmTE2VTx?= MVnJR|UxRTBwMUCyJO69VQ>? MmDWNlE1PDh3OUG=
SK-N-MC NXzsO|doT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYexNEDPxE1? M1G4S|k3KGh? NHe3SVZFVVOR MkXFTWM2OD1yLkC3NkDPxE1? MoO1NlE1PDh3OUG=
CHLA-9 NW\hWJBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PXVVExKM7:TR?= MmLhPVYhcA>? NV:wUm5rTE2VTx?= MXfJR|UxRTBwMEG4JO69VQ>? NITiS3IzOTR2OEW5NS=>
CHLA-10 NGO0WIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{ToZ|ExKM7:TR?= NX7Qb2lwQTZiaB?= Ml6xSG1UVw>? MWjJR|UxRTBwME[wJO69VQ>? NXP4UFRmOjF2NEi1PVE>
CHLA-25 MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrINWMyOCEQvF2= MXO5OkBp NXz4bHVKTE2VTx?= Ml7yTWM2OD1yLkG2PEDPxE1? NEnSS5MzOTR2OEW5NS=>
CHLA-32 NVP4UG9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDZNVAh|ryP NWTuS3dyQTZiaB?= MlrSSG1UVw>? MmT6TWM2OD1yLkGzOkDPxE1? NHji[|gzOTR2OEW5NS=>
CHLA-56 M{HVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTWNVAh|ryP NYTLbo5TQTZiaB?= MVjEUXNQ M2rBN2lEPTB;MUCg{txO NV7FS4FMOjF2NEi1PVE>
CHLA-258 NEXwZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vTelExKM7:TR?= M{L5[Fk3KGh? MUDEUXNQ Mn\iTWM2OD1yLkGzNkDPxE1? M1;vXlIyPDR6NUmx
COG-E-352 MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLmNVAh|ryP NHzxNYQ6PiCq M3fuSmROW09? M1fKPGlEPTB;MD6wOFMh|ryP MmDFNlE1PDh3OUG=
CHLA-90 NGLY[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOxNEDPxE1? NI\Dd406PiCq MVTEUXNQ M3Lne2lEPTB;MD6wOlEh|ryP M1vibVIyPDR6NUmx
CHLA-119 Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvHNVAh|ryP NGK1e5g6PiCq MXrEUXNQ NIDCRVJKSzVyPUCuNFIzKM7:TR?= M3T2dVIyPDR6NUmx
CHLA-122 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG4NVAh|ryP M3;pclk3KGh? NXfQUYhYTE2VTx?= M3jZ[GlEPTB;MD6wNVkh|ryP MnjvNlE1PDh3OUG=
CHLA-136 M{XMdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jtRlExKM7:TR?= NFfKdZg6PiCq M3u2WGROW09? M2DVV2lEPTB;MD6wN|kh|ryP NHjTPHAzOTR2OEW5NS=>
CHLA-140 M3zjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHDeWcyOCEQvF2= MkjWPVYhcA>? NFHtfHJFVVOR Mo\4TWM2OD1yLkCyOkDPxE1? MkjUNlE1PDh3OUG=
LA-N-6 M1rqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\jUlIyOCEQvF2= M{n6S|k3KGh? NX;WToRyTE2VTx?= MWjJR|UxRTBwMEW0JO69VQ>? M1vtPFIyPDR6NUmx
NB-1643 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[xNEDPxE1? NY\tTWppQTZiaB?= M{nyRWROW09? M1TpOmlEPTB;MD6wN|ch|ryP M{\6RlIyPDR6NUmx
NB-EBc1 NX3VdogyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHyWZJSOTBizszN MXu5OkBp NIPnTlRFVVOR NHq1OnJKSzVyPUCuNFUxKM7:TR?= NVzrXndVOjF2NEi1PVE>
SK-N-BE-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnXboUyOCEQvF2= M1PCblk3KGh? MWLEUXNQ NFLlelhKSzVyPUCuNFI5KM7:TR?= NGPDPZQzOTR2OEW5NS=>
SK-N-BE-2 NVrIdndUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH5V3EyOCEQvF2= MnvlPVYhcA>? NIX5XoZFVVOR M4Tob2lEPTB;MD6wN|Yh|ryP Ml7aNlE1PDh3OUG=
SMS-KAN MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3KwSVExKM7:TR?= NEfURYw6PiCq MkLPSG1UVw>? NUXJcWxwUUN3ME2wMlA{PCEQvF2= NVzIXY1uOjF2NEi1PVE>
SMS-KANR M4H6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPlR|AxOTBizszN MV25OkBp NELGfoVFVVOR M3W3cmlEPTB;MD6wNlYh|ryP MnXqNlE1PDh3OUG=
SMS-KCN MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnSZ3gyOCEQvF2= NIO1NZU6PiCq MVnEUXNQ NX\u[25UUUN3ME2wMlAyQSEQvF2= MYqyNVQ1QDV7MR?=
SMS-KCNR NXXr[md5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrFWY9bOTBizszN MlvmPVYhcA>? Ml76SG1UVw>? NGPjZ4ZKSzVyPUCuNFExKM7:TR?= NFrWZm8zOTR2OEW5NS=>
SMS-LHN MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rKNlExKM7:TR?= MXe5OkBp M16xXWROW09? NUfvRoNGUUN3ME2wMlA{OiEQvF2= NGTCS4szOTR2OEW5NS=>
SMS-MSN MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnXfHVkOTBizszN MX[5OkBp MVvEUXNQ NYf1XGJ{UUN3ME2wMlAzOiEQvF2= M4H5XVIyPDR6NUmx
SMS-SAN MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLaZXV6OTBizszN M2DC[Fk3KGh? Mlm2SG1UVw>? MVjJR|UxRTBwMEKwJO69VQ>? Ml\vNlE1PDh3OUG=
Granta-4 M4DkbWN6fG:2b4jpZ{BCe3OjeR?= MYWxNEDPxE1? M33Be|ch\A>? MnG5TWM2OD1yLkC0NEDPxE1? NF3Jc44zOTJ7MUi2Oy=>
DB NXq3d5d2S3m2b4TvfIlkKEG|c3H5 NVzUTVJ5OTBizszN MWW3JIQ> MW\JR|UxRTBwMESyJO69VQ>? M1fBWFIyOjlzOE[3
RL MmrlR5l1d3SxeHnjJGF{e2G7 NXnBfpk1OTBizszN NFvEVVY4KGR? NWKxbpJmUUN3ME2wMlAyPSEQvF2= NU\pfFRzOjF{OUG4Olc>
K562 NEfiVpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XpO|ExKM7:TR?= NFz2e|I6PiCq M4nCXGlEPTB;MD6wPFch|ryP NWrZWoN3OjFyOUG2N|M>
LAMA-84 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWWxNEDPxE1? M1[2WFk3KGh? NX;DW3pTUUN3ME2wMlA2PyEQvF2= M2DlN|IyODlzNkOz
MM15 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLpOEDPxE1? M{jHOlczKGh? Ml\tSG1UVw>? MYLJR|UxRTBwMUOg{txO NVvmcI55OjB|OEK4OFQ>
OPM1 NH7JZ5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTnOEDPxE1? NWnUdHhqPzJiaB?= M3uwcGROW09? M1jKXmlEPTB;MD6wN{DPxE1? NIfiOZEzODN6Mki0OC=>
RPM1 NYfjO|NiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzvOnB2PCEQvF2= NUDTVVFjPzJiaB?= MmP5SG1UVw>? MnPYTWM2OD1zMD6zNkDPxE1? MkjUNlA{QDJ6NES=
INA6 M{PJRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfYboZNPCEQvF2= NH2zRoQ4OiCq NXyyVldzTE2VTx?= NIjXWWdKSzVyPUCuNFAzKM7:TR?= NUf5TZljOjB|OEK4OFQ>
OPM2 M4HvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWK0JO69VQ>? MUC3NkBp MVPEUXNQ MlLvTWM2OD12LkO3JO69VQ>? M37UR|IxOzh{OES0
MM1R MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvnW3VNPCEQvF2= M3vl[|czKGh? MmP3SG1UVw>? NWKxcpI2UUN3ME2xMlY5KM7:TR?= NXPwZXN4OjB|OEK4OFQ>
DOX40 NXS4ZVlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkO2OEDPxE1? NX;4OFloPzJiaB?= MkC5SG1UVw>? MYfJR|UxRTVwNEig{txO MUCyNFM5Ojh2NB?=
LR5 NFPOPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrZc4Y1KM7:TR?= MlnpO|IhcA>? MULEUXNQ Mm\NTWM2OD1{LkWzJO69VQ>? MmfzNlA{QDJ6NES=
U266 NV\B[2xjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWmzcHVuPCEQvF2= MlPDO|IhcA>? MmLFSG1UVw>? MnLPTWM2OD1zLkSzJO69VQ>? Mn;JNlA{QDJ6NES=
RD NFy3[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\a[lExKM7:TR?= Mo\zPVYhcA>? NF;uOYJKSzVyPUCuNlI5KM7:TR?= NYjDeFFROjBzMEizN|g>
Rh41 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjydoEyOCEQvF2= NXuwSopuQTZiaB?= MV7JR|UxRTBwMEmwJO69VQ>? NHywWJAzODFyOEOzPC=>
Rh30 NGf6XGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVWxNEDPxE1? MVi5OkBp NWftVFlSUUN3ME2wMlI{OCEQvF2= NFe0R3ozODFyOEOzPC=>
BT-12 NWn6V|ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTtNVAh|ryP M33oTlk3KGh? MVXJR|UxRTBwME[wJO69VQ>? M{HibVIxOTB6M{O4
CHLA-266 MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYqxNEDPxE1? NVjTTWNTQTZiaB?= NVPyeJVxUUN3ME2wMlA4OiEQvF2= NITIcYYzODFyOEOzPC=>
TC-71 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYmxNEDPxE1? NWe5ZZpHQTZiaB?= NH7QeXdKSzVyPUCuNVAzKM7:TR?= NGnXfXQzODFyOEOzPC=>
SJ-GBM2 M3LSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\ENVAh|ryP NVTnWo02QTZiaB?= NG\mNY9KSzVyPUCuNFUxKM7:TR?= Mm\6NlAyODh|M{i=
NALM-6 NHLzdlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfxWJQyOCEQvF2= NHjp[Gc6PiCq MXPJR|UxRTBwME[yJO69VQ>? M1H4NVIxOTB6M{O4
COG-LL-317 MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjKenR1OTBizszN MXW5OkBp Mlv4TWM2OD1yLkC0O{DPxE1? NHq3d4gzODFyOEOzPC=>
RS4-11 Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP5[GsyOCEQvF2= MUS5OkBp NV3RTXhzUUN3ME2wMlAyQCEQvF2= Mo\5NlAyODh|M{i=
MOLT-4 MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rUZVExKM7:TR?= MlPjPVYhcA>? NVmyZ2k1UUN3ME2wMlAzPiEQvF2= NH;odYgzODFyOEOzPC=>
CCRF-CEM NWTrTGd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYSxNEDPxE1? NXS3R4g6QTZiaB?= M2WwOmlEPTB;MD6wPVQh|ryP NX\6[VJCOjBzMEizN|g>
Kasumi-1 MnrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XGWVExKM7:TR?= NIfqXoc6PiCq NFvTOHVKSzVyPUCuNVA{KM7:TR?= M3\vWFIxOTB6M{O4
Karpas-299 NYLxNnFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[2NVAh|ryP NE\URWI6PiCq M{fuV2lEPTB;MD6wN|gh|ryP NYTYWXBuOjBzMEizN|g>
Ramos-RA1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[5[IMyOCEQvF2= MX:5OkBp NVHEUJplUUN3ME2wMlEzPyEQvF2= MXiyNFExQDN|OB?=

... Click to View More Cell Line Experimental Data

In vivo MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. [2]

Protocol

Kinase Assay:[1]
+ Expand

Aurora A radioactive Flashplate enzyme assay:

Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:[2]
+ Expand
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using 3[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells
  • Formulation: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate
  • Dosages: ~30 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (52.03 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 15% Captisol 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 518.92
Formula

C27H20ClFN4O4

CAS No. 1028486-01-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02860000 Not yet recruiting Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) December 2016 Phase 2
NCT02812056 Not yet recruiting Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. September 2016 Phase 1
NCT02700022 Recruiting Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc. July 2016 Phase 1
NCT02719691 Recruiting Metastatic Breast Cancer|Solid Tumors University of Colorado, Denver May 2016 Phase 1
NCT02560025 Recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Takeda December 2015 Phase 2
NCT02551055 Active, not recruiting Neoplasms, Advanced or Metastatic Millennium Pharmaceuticals, Inc.|Takeda October 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Alisertib (MLN8237) | Alisertib (MLN8237) supplier | purchase Alisertib (MLN8237) | Alisertib (MLN8237) cost | Alisertib (MLN8237) manufacturer | order Alisertib (MLN8237) | Alisertib (MLN8237) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID